The pharmacokinetics and pharmacodynamics of diltiazem and its metabolites in healthy adults after a single oral dose
- PMID: 2791444
- DOI: 10.1038/clpt.1989.159
The pharmacokinetics and pharmacodynamics of diltiazem and its metabolites in healthy adults after a single oral dose
Abstract
A potential complicating factor in the characterization of the pharmacokinetics and pharmacodynamics of diltiazem after an oral dose in the presence of two metabolites, N-demethyldiltiazem and desacetyldiltiazem, in plasma. Both N-demethyldiltiazem and desacetylditiazem have been shown to have pharmacologic activity in animal tissues. It is therefore possible that these metabolites contribute to the pharmacologic effect of diltiazem, but this possibility has not been explored. The purpose of this study was to investigate the pharmacokinetics and pharmacodynamics of diltiazem, N-demethyldiltiazem, and desacetyldiltiazem. Particular attention was paid to the effect of diltiazem on atrioventricular conduction. Six healthy men received a 120 mg oral dose of diltiazem. Concentrations of diltiazem, N-demethyldiltiazem, and desacetyldiltiazem in plasma and urine were measured by a sensitive HPLC method. Measures of pharmacologic response (heart rate, blood pressure, and PR interval) were obtained at each blood sampling time. Mean (+/- SD) peak plasma concentrations of diltiazem, N-demethyldiltiazem, and desacetyldiltiazem were 174.3 +/- 72.7, 42.6 +/- 10.0, and 14.9 +/- 3.3 ng/ml, respectively. The apparent half-lives of diltiazem, N-demethyldiltiazem, and desacetyldiltiazem were 6.5 +/- 1.4 hours, 9.4 +/- 2.2 hours, and 18 +/- 6.2 hours, respectively. Both N-demethyldiltiazem and diltiazem were eliminated by net secretion, whereas the renal clearance of desacetyldiltiazem did not exceed clearance by filtration. Both N-demethyldiltiazem and desacetyldiltiazem are bound to plasma proteins, with unbound fractions of 0.323 +/- 0.035 and 0.230 +/- 0.021. These values are similar to the unbound fraction of diltiazem (0.254 +/- 0.027). No significant effect of diltiazem on blood pressure or heart rate was noted. However, a prolongation of the PR interval was observed in all six subjects. Furthermore, an apparent clockwise hysteresis in the concentration-effect relationship was found in four of the six subjects. These findings suggest that some form of acute tolerance to the electrophysiologic effect of diltiazem develops, but the results of pharmacodynamic modeling suggest that this is not caused by the antagonistic effects the metabolites.
Similar articles
-
Effects of propranolol on the disposition and negative dromotropic activity of diltiazem in the dog during multiple dosing.Drug Metab Dispos. 1993 Jan-Feb;21(1):156-61. Drug Metab Dispos. 1993. PMID: 8095211
-
Pharmacokinetics of diltiazem and its metabolites after repeated single dosing in healthy volunteers.Ther Drug Monit. 1989 Sep;11(5):551-7. Ther Drug Monit. 1989. PMID: 2815230
-
Pharmacokinetics and pharmacodynamics of intravenous diltiazem in patients with atrial fibrillation or atrial flutter.Circulation. 1992 Nov;86(5):1421-8. doi: 10.1161/01.cir.86.5.1421. Circulation. 1992. PMID: 1423955 Clinical Trial.
-
Pharmacokinetics of diltiazem and its metabolites after single and multiple dosing in healthy volunteers.Ther Drug Monit. 1989 Sep;11(5):558-66. Ther Drug Monit. 1989. PMID: 2815231
-
Calcium antagonists. Pharmacokinetic properties.Drugs. 1983 Feb;25(2):113-24. doi: 10.2165/00003495-198325020-00002. Drugs. 1983. PMID: 6339196 Review.
Cited by
-
Pharmacokinetics and metabolism of diltiazem in rabbits after a single intravenous or single oral administration.Eur J Drug Metab Pharmacokinet. 1991 Jan-Mar;16(1):69-74. doi: 10.1007/BF03189877. Eur J Drug Metab Pharmacokinet. 1991. PMID: 1936064
-
Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships.J Pharm Pharm Sci. 2014;17(1):34-91. J Pharm Pharm Sci. 2014. PMID: 24735761 Free PMC article.
-
Statistical approaches to pharmacodynamic modeling: motivations, methods, and misperceptions.Cancer Chemother Pharmacol. 1993;33(1):1-9. doi: 10.1007/BF00686015. Cancer Chemother Pharmacol. 1993. PMID: 8269582 Review.
-
Pharmacomicrobiomics: Exploiting the Drug-Microbiota Interactions in Antihypertensive Treatment.Front Med (Lausanne). 2022 Jan 19;8:742394. doi: 10.3389/fmed.2021.742394. eCollection 2021. Front Med (Lausanne). 2022. PMID: 35127738 Free PMC article. Review.
-
Decreased systemic clearance of diltiazem with increased hepatic metabolism in rats with uranyl nitrate-induced acute renal failure.Pharm Res. 1992 Dec;9(12):1599-606. doi: 10.1023/a:1015868525978. Pharm Res. 1992. PMID: 1488404
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials